This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Sep;43(9):951-5.

doi: 10.1046/j.1528-1157.2002.24302.x.

Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials

Jacqueline A French

PMID: 12199719
DOI: 10.1046/j.1528-1157.2002.24302.x

Editorial

Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials

Jacqueline A French. Epilepsia. 2002 Sep.

. 2002 Sep;43(9):951-5.

doi: 10.1046/j.1528-1157.2002.24302.x.

Author

Jacqueline A French

PMID: 12199719
DOI: 10.1046/j.1528-1157.2002.24302.x

No abstract available

PubMed Disclaimer

Comment on

A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
Wilton LV, Shakir S. Wilton LV, et al. Epilepsia. 2002 Sep;43(9):983-92. doi: 10.1046/j.1528-1157.2002.01702.x. Epilepsia. 2002. PMID: 12199723

Similar articles

Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy.
[No authors listed] [No authors listed] Epilepsia. 1998 Jul;39(7):799-803. doi: 10.1111/j.1528-1157.1998.tb01167.x. Epilepsia. 1998. PMID: 9670910 No abstract available.
Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML, Gurka MJ, Goodkin HP. Buck ML, et al. Neurology. 2007 May 1;68(18):1536-7. doi: 10.1212/01.wnl.0000260700.58495.f6. Neurology. 2007. PMID: 17470758 No abstract available.
Obstacles encountered in designing antiepileptic drug trials.
French JA. French JA. Epilepsy Res Suppl. 1993;10:81-9. Epilepsy Res Suppl. 1993. PMID: 8251107 Review. No abstract available.
What's the problem with generic antiepileptic drugs?: a call to action.
Berg MJ. Berg MJ. Neurology. 2007 Apr 17;68(16):1245-6. doi: 10.1212/01.wnl.0000262876.37269.8b. Neurology. 2007. PMID: 17438211 No abstract available.
Postmarketing surveillance for drug abuse.
Arfken CL, Cicero TJ. Arfken CL, et al. Drug Alcohol Depend. 2003 Jun 5;70(3 Suppl):S97-105. doi: 10.1016/s0376-8716(03)00102-9. Drug Alcohol Depend. 2003. PMID: 12759200 Review.

See all similar articles

Cited by

Postmarketing Results: Useful, But Proceed with Caution.
French JA. French JA. Epilepsy Curr. 2003 Nov;3(6):206-207. doi: 10.1046/j.1535-7597.2003.03611.x. Epilepsy Curr. 2003. PMID: 15346154 Free PMC article. No abstract available.
Diffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice.
Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA. Knoester PD, et al. Eur J Clin Pharmacol. 2004 Dec;60(10):751-8. doi: 10.1007/s00228-004-0839-8. Epub 2004 Nov 20. Eur J Clin Pharmacol. 2004. PMID: 15619137
Postmarketing adverse drug reactions: A duty to report?
Klein E, Bourdette D. Klein E, et al. Neurol Clin Pract. 2013 Aug;3(4):288-294. doi: 10.1212/CPJ.0b013e3182a1b9f0. Neurol Clin Pract. 2013. PMID: 24195018 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information